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SUMMARY
Background: Sporotrichosis is a subacute or chronic disease caused by a dimorphic fungus, Sporothrix schenckii. The first and 
most traditional treatment is potassium iodide in satured solution (SSKI) used by DE BEURMANN in 1907. For its effectiveness, it 
is still used for cutaneous sporotrichosis. Objective: To evaluate the treatment of cutaneous sporotrichosis with SSKI in relation to 
clinical cure, side effects, length of treatment and reactivation. Methods: We conducted a retrospective analysis of medical records 
over a 24-year period (1981-2005). Patients of all ages who were treated in the hospital´s division of dermatology were included in 
the study providing that they had a positive culture of S. schenckii. Satured solution of potassium iodide (3 to 6g per day) was the 
treatment prescribed. For children, half of the dose was prescribed. Results: The lymphocutaneous disease was prevalent, the cure 
rate was 94.7%, side effects were described in 5.5% of the cases, mean length of treatment was 3.5 months and possible reactivation 
was observed in 11.1%. Conclusion: SSKI is an effective drug, with many side effects, but with low frequency. Resolution was for 
maximum six months of treatment. SSKI has been found to be a very effective drug in this retrospective study of culture-proven cases 
of cutaneous and lymphocutaneous sporotrichosis. It should be used as first drug of choice especially in resource-limited settings. 
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INTRODUCTION
Sporotrichosis is a subacute or chronic disease of human beings 
and animals caused by the dimorphic fungus Sporothrix schenckii. 
The infection is usually localized in the skin and subcutaneous tissue. 
Systemic disease is rare and it may be developed by inhalation of spores 
through the respiratory tract2.
It occurs worldwide, but it is endemic in South Africa19, Central 
America, South America6,18,23, Japan and India21, more commonly seen 
in tropical and subtropical zone regions24.
Since 1998 we have been observing an increasing number of cases 
of sporotrichosis in Rio de Janeiro, Brazil and surrounding areas. Most 
cases were from underprivileged areas on the outskirts of the city, and 
mostly originated from feline sporotrichosis1. 
Zoonotic transmission has been reported in isolated cases. Many 
animals are considered susceptible such as horses, dogs, cats, rats, pigs, 
cows and armadillos20. Sporotrichosis affects people of any age, either 
male or female without any predisposing factor, except in the systemic 
form. It is associated with agricultural, gardening and other activities that 
promote traumatic contact with plant material or soil15.
Sporotrichosis is classified in cutaneous forms (lymphocutaneous 
and fixed cutaneous), extracutaneous and disseminated forms. The 
lymphocutaneous form is the most common2. 
For a definitive diagnosis of this mycosis, fungal culture should be 
performed22,24. Colonies performed at room temperature present a creamy 
white color that convert into the characteristic brown-black leathery 
colonies. At 37 ºC, the colony turns to a yeast-form and a creamy aspect 
with irregular surface13.
The demonstration of the long, thin, hyaline hyphae and conidia 
displaying a bouquet configuration, like daisies on the microscope 
associated with the fungus dimorphism confirms the diagnosis28.
Treatment of sporotrichosis can be difficult, mainly due to patient 
compliance over long duration treatment. In addition, it is expensive, 
especially with use of the new antifungal drugs9. 
Cutaneous and lymphocutaneous sporotrichosis should be treated 
with itraconazole or SSKI (satured solution of potassium iodide) in 
countries in which the latter is the standard of care11. It was first used by 
DE BEURMANN in 1907 and is still one of the most prescribed for its 
effectiveness and low cost7,22. 
The disadvantages of potassium iodide are the length of the 
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treatment, relapses if not taken after clinical cure for at least two weeks 
and the limited effectiveness in the systemic form7. Besides that, SSKI 
is inconvenient to take because of its taste and many side effects3. 
Some cases showing association of SSKI with itraconanazole8,12 and 
terbinafine17 were described.
The objective of our study was to describe the treatment of cutaneous 
sporotrichosis with SSKI in relation to clinical cure, side effects, length 
of treatment and relapse.
MATERIAL AND METHODS
Patients were identified through a retrospective review of fungal tests 
performed at the laboratory of mycology of the division of dermatology 
of the hospital Santa Casa de São Paulo during a 24-year-period (January 
1, 1981 - December 31, 2005). The study was approved by the Ethics and 
Research Committee of the “Irmandade da Santa Casa de São Paulo”.
Patients of all ages who were treated in the hospital´s division of 
dermatology were included in the study provided that they had a positive 
culture of S. schenckii, obtained through a specimen of a draining skin lesion 
(scraping) or needle biopsy of a nonexudative lesion. The direct microscopic 
examination using potassium hydroxide was used in all patients. The patients 
who did not follow-up or presented a form other than the cutaneous and 
lymphocutaneous sporotrichosis were excluded from this study. 
Samples obtained from skin lesions for isolation of S. schenckii were 
inoculated on Agar Mycobiotic (Difco) for three to five days, incubated 
at 25 oC, and submitted to macroscopic and microscopic examination.
On identification of a case of sporotrichosis, we reviewed the 
corresponding medical records (if available) and recorded the data 
on a standardized form. Side effects were considered when signs and 
symptoms were described in the records. There was a protocol where 
the dosage of SSKI and the side effects could be written.
The treatment for all patients was SSKI (3-6g/day for adults and half 
of the dose for children maintained for two weeks after total regression 
of the lesions). Patients considered cured were the ones whose follow-
up was done every three months after clinical cure (total healing of the 
lesion) for one year. Patients with reinfection or incomplete treatment 
were those who had clinical cure initially, but during follow up showed 
sporotrichosis lesions. We considered treatment incomplete when the 
medication was suspended before the total healing of the lesion or when 
it was not maintained for two weeks after the regression of the lesion.
The data collected from each patient were analyzed using software 
(Epi-Info). Statistical methods used for this analysis included frequency, 
mean, SD, percentage, median, minimum, maximum, Chi-square test 
and Fisher´s exact test. A value of p < 0.05 was considered significant.
RESULTS
Among the 51 cases of sporotrichosis identified, some data 
information were not identified in the 26 records available in the hospital. 
Among these 26 records, only 18 completed the whole treatment and 
were followed-up for a one-year-period. One patient had the systemic 
form and was also excluded. 
There was a male preponderance among the 18 patients. Males 
were 72.2% and females were 27.8%. Most cases were diagnosed in 
the 1980´s and 1990´s.
Mean age was 34.7 years and median 34 years. Age ranged from one 
to 73 years. 27.8% were under 18 years.
Occupations most common were those that had activities involving 
trauma and exposure to contaminated soil or vegetation such as gardening, 
farming and carpentry (66.7%), followed by students (25%) and other 
professions (8.3%). 
The direct microscopic examination was negative in 100%.
The most frequent form of cutaneous sporotrichosis was the 
lymphocutaneous form (66.7%) followed by the fixed cutaneous form 
(33.3%). 
Among the 18 cases that finished the entire treatment, the shortest 
period of treatment was one month, mean was 3.5 months and maximum 
was six months. 61.1% of the patients were treated for a maximum of 
three months.
There was a major deficiency in data of the side effects that has not 
been available in the records. There were no side effects described in the 
patient’s records in 94.5%. The only patient who presented side effects 
was a 14-year-old female with fixed cutaneous form. She was taking 3 g/
day of SSKI. Diarrhea, nausea and headache were described in the records. 
Medication was suspended for a week and then the dose was decreased to 
2g/day for five months. With this dose, there was not complaint.
All patients responded to SSKI treatment initially. Two patients 
(11.1%) had new lesions after SSKI short treatment. The first case was 
a one-year-old female with the fixed cutaneous form on the face. Seven 
months after she finished a one-month-period treatment, the mother 
noticed a lesion on the face once again. SSKI was prescribed for another 
two months and she was cured.
The second case was a 36-year-old male with the fixed cutaneous 
form in the leg after trauma. The length of the treatment was two months. 
Two years after the end of the treatment, new lesions appeared. He was 
treated with SSKI for three more months and was also cured. 
When analyzing the length of treatment and the form of the disease, 
we noticed that nine patients had fixed cutaneous form with a mean 
treatment of three months. The minimum was one month, median was 
three months and maximum was five months.
Eight patients with lymphocutaneous lesions were treated for a 
maximum three months and four patients for more than four months. 
50% of the patients with localized form were treated for maximum 
three months.
The distribution of patients according to length of treatment and 
the variables (sex, age and reinfection) is in Table 1. For this analysis, 
the length of the treatment was divided into two groups (up to three 
months and more than four months). There was no significant statistical 
association.
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DISCUSSION
This is a case series of cutaneous and lymphocutaeous sporotrichosis, 
a retrospective review. Treatment with SSKI has been found to be 
effective.
In our study we observed that more cases were treated in the 80´s 
when compared to more recent years. This may have occurred because 
of the urbanization and more know-how of clinicians to diagnose and 
treat the disease. 
Ecological factors that have been associated with its development are 
temperatures between 26 oC and 27 oC and presence of organic material. 
For this reason, sporotrichosis is considered to be acquired during outdoor 
leisure or occupational activities that promote frequent and traumatic 
contact with plant material or soil5. In agreement with these observations, 
we found that 66.7% of patients had an occupational hazard.
The sex distributions of the disease vary from region to region 
depending on conditions of exposure21. In our study, most patients were 
male (72.2%), and that is described in many other studies4,5,15. Some 
authors, on the other hand, find no prevalence of either male of female7,8. 
Higher prevalence in females has been reported among Indian women 
working in agriculture21 and in a zoonotic epidemic in Rio de Janeiro, 
probably from continuous contact with infected cats25.
In relation to age, we observed that most patients were adults. Adults 
represent the highest proportion of cases in most endemic areas, but it 
may vary also from area and population. National studies describe that 
the mean age is higher each decade. Between 1960 and 1970, children 
and young adults were the most affected4,15. In the study published by 
MARQUES et al. (1997)19, the higher prevalence was in older patients. 
The median age in Rio de Janeiro was 39 years25. In Japan, most of the 
patients were children and adults above 50 years27. 
Direct microscopic examination of the specimen is often of little or 
no value in sporotrichosis. In our study, it was negative in 100%. On the 
other hand, the fungal culture, considered the gold standard exam for 
diagnosis, was used in our study.
The commonest presentation of the disease was the lymphocutaneous 
form (66.7%), followed by the fixed cutaneous form (33.3%) similar to 
studies. On the contrary, in Australia4, Japan27
 
and the State of Rio Grande 
do Sul, Brazil14, this prevalence was not noticed.
Although itraconazole turns out to be the treatment of choice for the 
cutaneous forms of sporotrichosis, it is still an expensive treatment (15 
capsules of Itraconazole costs US$ 30.00 in Brazil). Potassium iodide, 
therefore, is commonly prescribed in developing countries. 
Potassium iodide is usually administered in the form of a saturated 
solution (SSKI) at a dose of 47 mg/drop. After ingestion, potassium 
iodide is readily absorbed in the intestinal tract and distributed rapidly 
through the extracellular space. It concentrates in the thyroid gland, 
salivary glands, gastric mucosa, choroid plexus, mammary glands, and 
the placenta. Ninety percent of the orally administered dose is excreted 
in the urine. Sweat, breast milk, and feces account for the remainder of 
the excretion26. 
The initial dose for adults is five drops three times a day, increasing 
one drop per dose per day7. Usually the dose varies from two to three 
grams per day13 and it may reach six grams per day16. Administration with 
fruit juices or milk may mitigate against gastrointestinal side effects. It 
is recommended that the therapeutic dose should be maintained for up 
to four weeks beyond the time of total clinical cure22,24. 
Children with cutaneous and lymphocutaneous sporotrichosis should 
be treated with itraconazole. Dosages of either 100 mg daily or 6-10 mg/
kg daily (to a maximum of 400 mg daily) have been used. SSKI has also 
been used as treatment for dosages of one drop administered three times 
daily, up to a maximum of one drop/kg or 40-50 drops administered three 
times daily11. RAMOS-E-SILVA et al. (2007)24 recommended maximum 
dose of 25 drops three times daily. 
In the present study all patients were exclusively treated with SSKI 
and initially it was successful in all 18 patients, with total healing of the 
cutaneous lesions. Among them, the mean duration was 3.5 months. In 
61.1% of the patients were treated for maximum three months. The two 
patients that had new lesions after treatment with SSKI, received a short 
period of treatment, but after taking another regular SSKI therapy there 
was no recurrence in any of them. Some papers say that sporotrichosis 
immunity is not prolonged. SSKI should always be continued for another 
two weeks after the clinical cure to reduce relapse.
MARQUES et al. (1997)19 described cure with SSKI in two months 
in most of the patients. In the study realized by DA ROSA et al. (2005)5, 
Table 1
Distribution according to length of treatment, sex, age and reinfection in 26 patients with sporotrichosis
Treatment ≤ 3 months Treatment ≥ 4 months Total
Sex Male 9 (69.2%) 4 (30.8%) 13 (100%)
Female 2 (40%) 3 (60%) 5 (100%)
Age 1 - 18 y 3 (60%) 2 (40%) 5 (100%)
19 - 60 y 6 (60%) 4 (40%) 10 (100%)
> 60 y 2 (66.7%) 1 (33.3%) 3 (100%)
Reinfection/Relapse Yes 2 (100%) 0 2 (100%)
No 9 (56.2%) 7 (43.8%) 16 (100%)
y - years old.
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all 304 patients were cured in up to 16 weeks. Even in the United States, 
a country with higher income, one patient was treated successfully with 
SSKI for eight weeks9.
Potassium iodide has significant side effects even though not found 
in our study. Usually, these reactions are not severe and the drug may 
be suspended or prescribed in lower doses7. It has also been reported 
to cause less common, but severe side effects, such as pulmonary 
edema, angioedema, lymphadenopathy, vasculitis, periarteritis nodosa, 
pustular psoriasis, metabolic acidosis, cardiac irritability and bullous 
pemphigoid26.
Prolonged usage leads to the interruption of the endogenous 
production of thyroid hormones, a phenomenon known as the Wolf-
Chaikoff effect6,24. It may also cause Jod-Basedow phenomenon because 
of absent autoregulation, thyreoiditis10, hypo or hyperthireoidism26. After 
suspension of the drug for one month, hormones usually normalize6. 
If therapy with potassium iodide continues for more than one month, 
however, a screening TSH is prudent to ensure that iodide-induced 
hypothyroidism does not ensue10.
Patients with renal function impairment or those taking angiotensin-
converting enzyme inhibitors or potassium-sparing diuretics are at 
increased risk for potassium toxicity26.
HABTE-GABR & WALSH (2001)9 presented one case treated with 
SSKI at a dose of 4 mL three times daily for eight weeks. There was a 
complete remission of the lymphocutaneous sporotrichosis and the only 
side effect was a bitter taste. 
Although many side effects were described such as gastrointestinal 
disturbance, coryza, rash, salivary enlargement and metallic taste, in a 
few cases the drug dose was lowered or suspended in this study. Although 
there was a major deficiency in data that has not been available, of the 18 
cured cases, there were no signs or symptoms related to SSKI described 
in patients files in 94.5%, which is similar to the literature. There was 
only one patient relating diarrhea and headache while on SSKI therapy. 
After reducing the dosage, there were no complaints. 
Most cases described in literature suspended SSKI because of 
intolerance and not reinfection. KOÇ et al. in 199912 presented a 
lymphocutaneous case treated with SSKI and itraconazole. Clinical cure 
was observed after two months. 
There was no statistic significance among sex, age and length of 
treatment. In males and all ages, the length of treatment up to three months 
was prevalent. So, even the older patients, who may have associated 
conditions, responded rapidly with SSKI. 
CONCLUSION
In the present study we conclude that with our 24-year experimence, 
the treatment of sporotrichosis with SSKI is effective, with total healing 
of the lesions in all patients. It has many side effects as described, but with 
low frequency. Resolution of the disease was noticed in maximum six 
months of treatment. Reinfection is possible, especially when treatment 
is for a short period. We recommend SSKI be used as first choice in 
resource-limited settings for cutaneous, lymphocutaneous sporotrichosis. 
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RESUMO
Tratamento da esporotricose cutânea com SSKI. Experiência de 
24 anos no Estado de São Paulo, Brasil.
Fundamentos: Esporotricose é doença subaguda ou crônica causada 
pelo fungo dimórfico Sporothrix schenckii. O primeiro e mais tradicional 
tratamento é o iodeto de potássio em solução saturada (SSKI) usado por 
De Beurmann em 1907. Por ser eficaz,ainda é muito utilizada no nosso 
meio para o tratamento da esporotricose cutânea. Objetivos: Avaliar 
o tratamento da esporotricose cutânea com SSKI em relação à cura 
clínica, efeitos colaterais, tempo de tratamento e recidiva. Métodos: A 
partir da revisão dos resultados de exames do laboratório de Micologia 
da Clínica de Dermatologia da Santa Casa de SP, durante 1981 a 2005, 
foram incluídos pacientes de qualquer idade com lesão cutânea sugestiva 
de esporotricose e cultura positiva para S. schenckii. Em todos pacientes 
o tratamento prescrito foi SSKI na dose de 3 a 6g/dia para adultos, por 
um período de até duas semanas após cura clínica. Em crianças foi 
utilizada a metade da dose. Resultados: Houve predomínio da forma 
cutânea localizada, taxa de cura de 94,7%, efeitos colaterais em 5,5%, 
média de tempo de tratamento de 3,5 meses e 11,1% de provável recidiva. 
Conclusão: A SSKI é eficaz, com diversos efeitos colaterais, porém de 
baixa frequência, permanecendo indicada para as formas cutâneas da 
esporotricose.
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